The state of Massachusetts currently has 10 active clinical trials seeking participants for Pulmonary Fibrosis research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260
Recruiting
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
04/24/2024
Locations: Massachusetts General Hospital - Pulmonary Associates, Boston, Massachusetts +3 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535
Recruiting
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Tufts Medical Center, Boston, Massachusetts +1 locations
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
All
Ages:
21 years and above
Trial Updated:
04/19/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +3 locations
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
NCT05389215
Recruiting
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
04/16/2024
Locations: Tufts Medical Center, Boston, Massachusetts +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
NCT01915511
Recruiting
This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts. For participants with non-IPF, chronic fibrosing ILD with progre... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
04/09/2024
Locations: Lahey Clinic, Burlington, Massachusetts
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/06/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +3 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
NCT04708782
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/01/2024
Locations: Tufts Medical Center, Boston, Massachusetts +1 locations
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect
NCT06265532
Recruiting
The primary purpose of this substudy is to determine if collagen-targeted PET using the type 1 collagen-targeted PET probe, Gallium-68 (68Ga)-labeled collagen binding probe 8 (CBP8) can inform as to drug effect of EGCG and assist in dose selection.
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
02/09/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
NCT05195918
Recruiting
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
02/02/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
NCT03535545
Recruiting
The goal of this study is to investigate the safety of [68Ga]CBP8 and its efficacy to detect collagen deposition in pulmonary fibrosis.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
12/01/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Pulmonary Fibrosis, Lung Cancer
Register for Updates